guest ::
| Home > Publications database > Proteomic profiling of high risk medulloblastoma reveals functional biology. > print |
| Home > Publications database > Proteomic profiling of high risk medulloblastoma reveals functional biology. > print |
| 001 | 127545 | ||
| 005 | 20240228140935.0 | ||
| 024 | 7 | _ | |a 10.18632/oncotarget.3927 |2 doi |
| 024 | 7 | _ | |a pmid:25970789 |2 pmid |
| 024 | 7 | _ | |a pmc:PMC4546489 |2 pmc |
| 024 | 7 | _ | |a altmetric:4015265 |2 altmetric |
| 037 | _ | _ | |a DKFZ-2017-03568 |
| 041 | _ | _ | |a eng |
| 082 | _ | _ | |a 610 |
| 100 | 1 | _ | |a Staal, Jerome A |b 0 |
| 245 | _ | _ | |a Proteomic profiling of high risk medulloblastoma reveals functional biology. |
| 260 | _ | _ | |a [S.l.] |c 2015 |b Impact Journals LLC |
| 336 | 7 | _ | |a article |2 DRIVER |
| 336 | 7 | _ | |a Output Types/Journal article |2 DataCite |
| 336 | 7 | _ | |a Journal Article |b journal |m journal |0 PUB:(DE-HGF)16 |s 1508852661_20352 |2 PUB:(DE-HGF) |
| 336 | 7 | _ | |a ARTICLE |2 BibTeX |
| 336 | 7 | _ | |a JOURNAL_ARTICLE |2 ORCID |
| 336 | 7 | _ | |a Journal Article |0 0 |2 EndNote |
| 520 | _ | _ | |a Genomic characterization of medulloblastoma has improved molecular risk classification but struggles to define functional biological processes, particularly for the most aggressive subgroups. We present here a novel proteomic approach to this problem using a reference library of stable isotope labeled medulloblastoma-specific proteins as a spike-in standard for accurate quantification of the tumor proteome. Utilizing high-resolution mass spectrometry, we quantified the tumor proteome of group 3 medulloblastoma cells and demonstrate that high-risk MYC amplified tumors can be segregated based on protein expression patterns. We cross-validated the differentially expressed protein candidates using an independent transcriptomic data set and further confirmed them in a separate cohort of medulloblastoma tissue samples to identify the most robust proteogenomic differences. Interestingly, highly expressed proteins associated with MYC-amplified tumors were significantly related to glycolytic metabolic pathways via alternative splicing of pyruvate kinase (PKM) by heterogeneous ribonucleoproteins (HNRNPs). Furthermore, when maintained under hypoxic conditions, these MYC-amplified tumors demonstrated increased viability compared to non-amplified tumors within the same subgroup. Taken together, these findings highlight the power of proteomics as an integrative platform to help prioritize genetic and molecular drivers of cancer biology and behavior. |
| 536 | _ | _ | |a 312 - Functional and structural genomics (POF3-312) |0 G:(DE-HGF)POF3-312 |c POF3-312 |f POF III |x 0 |
| 588 | _ | _ | |a Dataset connected to CrossRef, PubMed, |
| 650 | _ | 7 | |a Biomarkers, Tumor |2 NLM Chemicals |
| 700 | 1 | _ | |a Lau, Ling San |b 1 |
| 700 | 1 | _ | |a Zhang, Huizhen |b 2 |
| 700 | 1 | _ | |a Ingram, Wendy J |b 3 |
| 700 | 1 | _ | |a Hallahan, Andrew R |b 4 |
| 700 | 1 | _ | |a Northcott, Paul A |0 P:(DE-HGF)0 |b 5 |
| 700 | 1 | _ | |a Pfister, Stefan |0 P:(DE-He78)f746aa965c4e1af518b016de3aaff5d9 |b 6 |u dkfz |
| 700 | 1 | _ | |a Wechsler-Reya, Robert J |b 7 |
| 700 | 1 | _ | |a Rusert, Jessica M |b 8 |
| 700 | 1 | _ | |a Taylor, Michael D |b 9 |
| 700 | 1 | _ | |a Cho, Yoon-Jae |b 10 |
| 700 | 1 | _ | |a Packer, Roger J |b 11 |
| 700 | 1 | _ | |a Brown, Kristy J |b 12 |
| 700 | 1 | _ | |a Rood, Brian R |b 13 |
| 773 | _ | _ | |a 10.18632/oncotarget.3927 |g Vol. 6, no. 16, p. 14584 - 14595 |0 PERI:(DE-600)2560162-3 |n 16 |p 14584 - 14595 |t OncoTarget |v 6 |y 2015 |x 1949-2553 |
| 909 | C | O | |o oai:inrepo02.dkfz.de:127545 |p VDB |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 5 |6 P:(DE-HGF)0 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 6 |6 P:(DE-He78)f746aa965c4e1af518b016de3aaff5d9 |
| 913 | 1 | _ | |a DE-HGF |l Krebsforschung |1 G:(DE-HGF)POF3-310 |0 G:(DE-HGF)POF3-312 |2 G:(DE-HGF)POF3-300 |v Functional and structural genomics |x 0 |4 G:(DE-HGF)POF |3 G:(DE-HGF)POF3 |b Gesundheit |
| 914 | 1 | _ | |y 2015 |
| 915 | _ | _ | |a JCR |0 StatID:(DE-HGF)0100 |2 StatID |b ONCOTARGET : 2015 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0200 |2 StatID |b SCOPUS |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0300 |2 StatID |b Medline |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0310 |2 StatID |b NCBI Molecular Biology Database |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0199 |2 StatID |b Thomson Reuters Master Journal List |
| 915 | _ | _ | |a WoS |0 StatID:(DE-HGF)0111 |2 StatID |b Science Citation Index Expanded |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0150 |2 StatID |b Web of Science Core Collection |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1050 |2 StatID |b BIOSIS Previews |
| 915 | _ | _ | |a IF >= 5 |0 StatID:(DE-HGF)9905 |2 StatID |b ONCOTARGET : 2015 |
| 920 | 1 | _ | |0 I:(DE-He78)B062-20160331 |k B062 |l Pädiatrische Neuroonkologie |x 0 |
| 980 | _ | _ | |a journal |
| 980 | _ | _ | |a VDB |
| 980 | _ | _ | |a I:(DE-He78)B062-20160331 |
| 980 | _ | _ | |a UNRESTRICTED |
| Library | Collection | CLSMajor | CLSMinor | Language | Author |
|---|